Cardiomyocyte differentiation
Emmet automatically scales and differentiates human iPS cells to Cardiomyocytes with a range of applications from basic research and development, drug testing and cellular therapeutics
Problem
Induced pluripotent stem cells (iPSCs) offer a versatile foundation for regenerative/personalised medicine and cardiac research due to their ability to differentiate into cardiomyocytes. However, there are significant challenges in the complexity of both maintaining and differentiating iPSCs into various cell types, including cardiomyocytes. This has significant consequences for consistency, scalability, cost and ultimately limits iPSCs translation into clinical practice.
Solution
We applied a published cardiomyocyte differentiation protocol using Emmet, our closed-loop automated cell culture robotic scientific assistant, to address these limitations. The system was user-programmed to perform media exchanges and reagent delivery in line with a published protocol. Whilst eliminating the necessity for manual operator input during the culture process.
The proof
Assessment of the differentiated cells using flow cytometry, gene expression analysis, and immunostaining confirmed high-purity cardiomyocytes. In conjunction with beating cardiomyocytes. Emmet facilitates efficient and reproducible cardiomyocyte production, enabling its integration into scalable cardiac research and therapeutic workflows.
For published protocol see. Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L. B., Azarin, S. M., Raval, K. K., Zhang, J., Kamp, T. J., & Palecek, S. P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America, 109(27), E1848–E1
For app note download go to resource library: https://www.unicornb.io/resources?type=Resource-Library
